Apogenix Receives EUR 20.7 Million in Public Funding for Pivotal Study and Preparation for Market Production of Asunercept for the Treatment of COVID-19

RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations

Atriva Therapeutics strengthens advisory board with Piet Wigerinck

Newron Pharmaceuticals S.p.A.: Change in Newron Board of Directors

Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis

Marinomed to present at Munich capital market conference (MKK)

RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results

Abivax’s phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Symposium 2022

Avisa Diagnostics Reports on Status of Interim Filings

sterna biologicals receives approval for innovative phase II a study design in asthma combining a novel antisense-based treatment with a digital therapy